Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | MEDI-570: a novel antibody therapy in R/R T-cell lymphoma

Julio Chavez, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the results of a Phase I, dose-escalation study (NCT02520791) aiming to evaluate the safety and efficacy of an anti-ICOS monoclonal antibody, MEDI-570, in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL). In a group of 17 patients with either PTCL or AITL, no dose-limiting toxicities (DLTs) were reported and the maximum tolerated dose (MTD) was not reached. A partial response (PR) was seen in four AITL patients, regardless of the dosage used. Durable responses could also be seen in the participants who achieved PR. While 65% of the patients experienced side effects in the form of a low CD4+ T-cell count, the overall safety profile of MEDI-570 was found tolerable. Flow cytometry analysis showed that following MEDI-570 treatment, the populations of ICOS-positive T-cells were decreased but other cell types, including B-cells were not affected. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.